Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 30, 2012

Charles River Buys Accugenix for $17M

  • Charles River Laboratories acquired cGMP contract microbial identification and typing firm Accugenix for $17 million in cash. Charles River says the buyout will strengthen its own endotoxin and microbial detection (EMD) product portfolio by providing clients with microbial detection services for manufacturing in the biopharmaceutical, medical device, and other sectors.

    “The acquisition of Accugenix is the first step in our broader strategy to become the premier provider of rapid microbial and endotoxin detection products and services to the biopharmaceutical industry,” states James C. Foster, chairman, president and CEO at Charles River. “Over the next several years we intend to enhance our capabilities through both product extensions and acquisitions.”

    Accugenix specializes in the provision of bacterial and fungal identification and strain typing of services to a range of manufacturing industries. The firm says its library databases enable the identification of over 5,000 species.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »